Fred Hutchinson Cancer Center recently announced that they will be leading a National Cancer Institute (NCI)-funded study, testing certain multi-cancer detection (MCD) blood tests aimed to diagnose cancers early.
The Vanguard study will analyze the Avantect MCD Test by ClearNote Health and the Shield MCD Test by Guardant Health for 10 types of cancers: bladder, breast, colorectal, esophageal, stomach, liver, lung, ovarian, pancreatic and prostate. Participants will be aged 45-75 “with no cancer diagnosis in the past five years.” The goal of the study is to determine if the tests are effective for multiple patient types.
According to a release, the study will “help shape the rigorous design and implementation of future studies aimed at advancing early cancer detection, including a large national trial to determine if MCD tests decrease cancer burden and mortality.”
